Efficacy and safety of iguratimod in patients with primary Sjögren's syndrome: a multicentre randomised controlled trial.

RMD Open · 2025 · PMC12718576 · PMID 41423293

Europe PMC DOI

hedged sentence

0.1140

closest p · 2.3× alpha

0.1140

boldest claim

The sentences

did not reach statistical significancep=0.114not close (p > 0.1)

Efficacy outcomes In the primary endpoint analysis based on the ITT principle, the SSRI-30 response rate at week 24 was numerically higher in the IGU group (57.9%, 22/38) than in the HCQ group (40.0%, 16/40); however, this difference did not reach statistical significance (p=0.114) ( figure 2A ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.